Epix Abandons Anxiety For PDX-00023; Focus Now On Depression
Disappointing Phase III anxiety results lead to change; company eyes candidate as competitor to Forest’s Lexapro.
Disappointing Phase III anxiety results lead to change; company eyes candidate as competitor to Forest’s Lexapro.